Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in pediatric glycogen storage disease–associated inflammatory bowel disease
ChiCTR2400080773Phase 4Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in glycogen storage disease-associated inflammatory bowel disease (GSD-IBD), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Endoscopic features and SES-CD and Geboes scores. Started Feb 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease-associated inflammatory bowel disease (GSD-IBD)
Beyond the preview
Go deeper on ChiCTR2400080773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080773.